http://onlinelibrary.wiley.com/doi/10.1111/j.1432-2277.2010.01104.x/abstract
Keywords:
hepatitis B immunoglobulins;hepatitis B virus – prophylaxis;liver transplantation;monophosphoryl-lipid-A;recombinant S HBV vaccine
Summary
Conflicting results have been reported on vaccination against hepatitis B virus (HBV) as a prophylaxis against viral recurrence after liver transplantation. We investigated the efficacy of 1-year, monthly vaccination using an adjuvant 3-deacylated monophosphoryl-lipid-A (MPL) recombinant S vaccine initially administered together with hepatitis B immunoglobulins (HBIg) in 18 patients transplanted for HBV-related cirrhosis. All received 12 vaccine doses (HBsAg, 20 mcg plus MPL, 50 mcg): the initial six doses (phase I) were administered within 7 days after intravenous HBIg (2000 IU), while the last 6 (phase II) following HBIg withdrawal. All patients received lamivudine during the study. Anti-HBs titers were determined before each dose and then for 1 year after vaccination. After phase I anti-HBs titers were greater than 100 IU/l in all patients and in three (16.6%) were greater than 500 IU/l. After phase II 10 patients (55.5%) achieved anti-HBs titers greater than 100 IU/l and five (27.7%) greater than 500 IU/l. One year after vaccination eight patients (44.4%) maintained anti-HBs titers greater than 100 IU/l, with a median titer of 234 IU/l (102–1205), and 2 (11.1%) greater than 500 IU/l. One-year extended monthly vaccination with a MPL-adjuvant recombinant vaccine induces a sustained protective anti-HBs response in approximately half of transplant recipients.
normal vaccine doesn t work for sure
there is also a trial done in rome several years ago for transplanted patients with a boosted vaccine.
transplanted patients are in similar situation with hbsag negative but weaker immune system than normal carriers
they did vaccine monthly and most gained hbsab by 1 year.i have to look for the trial again to see doses and type of vaccine
the ideal vaccine needs both hbcag and hbsag and boosting substances
They just take the ordinary vaccine.
Even with the above paper, it can still be argued that these patients will eventually gain the antibodies without injecting the vaccine. Still, it does not seem to do any harm, I hope.
i guess boosting vaccine is needed, are they using the new vaccines with boosting ubstances and both hbsag, hbcag?
in pisa they told me about vaccines too but they also said it doesn t work.i think that thisomsin alpha, gcmaf and similar substances are needed to boost the vaccine
i ve heard of a vaccine from israel too to be used with rep9ac and myrcludex but i have no name of this new vaccine
This is interesting because some patients in China, on their own initiative, get vaccinated when they lose the S antigen without gaining S antibodies.